Revolution Medicines, INC Form 4 insider transactions

Revolution Medicines CFO Jack Anders exercised options and sold 10,000 shares of common stock for $98.00 per share under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,688 shares of common stock at $76.8169 per share to cover tax withholding obligations.

Revolution Medicines CEO Mark A. Goldsmith sold 15,394 shares of common stock to cover tax withholding obligations from RSU vesting.

A Revolution Medicines executive sold 5,447 shares of common stock at $76.8172 per share to cover tax withholding obligations from RSU vesting.

Revolution Medicines' Chief Operating Officer, Margaret A. Horn, sold 4,847 shares of common stock to cover tax withholding obligations related to RSU vesting.

Revolution Medicines' Chief Financial Officer, Jack Anders, sold 3,104 shares of common stock to cover tax withholding obligations from restricted stock unit vesting.

Revolution Medicines CFO Jack Anders exercised stock options and immediately sold the acquired shares under a pre-arranged 10b5-1 plan.

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and subsequently sold a portion of his common stock holdings, including shares held in trusts, under a 10b5-1 plan.

Revolution Medicines, Inc. CEO Mark A. Goldsmith exercised stock options and subsequently sold 20,000 shares of common stock on November 18, 2025, as part of a pre-arranged 10b5-1 trading plan.

Revolution Medicines General Counsel Jeff Cislini exercised options and sold 13,388 shares of common stock under a pre-arranged 10b5-1 trading plan.

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Financial Officer, Jack Anders, exercised stock options and sold 10,000 shares of common stock for a significant profit under a pre-arranged 10b5-1 trading plan.

Revolution Medicines, Inc. CEO Mark A. Goldsmith reported exercising stock options, selling 30,000 shares, and transferring 100,000 shares to family trusts, all executed under a pre-arranged 10b5-1 trading plan.

Revolution Medicines General Counsel, Jeff Cislini, executed a pre-planned sale of 12,000 common shares following the exercise of stock options.

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and subsequently sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, Inc., executed a pre-planned sale of 25,000 common shares after exercising stock options.

Revolution Medicines General Counsel Jeff Cislini sold 1,799 shares of common stock for $44.26 per share pursuant to a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Medical Officer, Wei Lin, sold 2,160 shares of common stock to cover tax obligations from restricted stock unit vesting.

Revolution Medicines' President of R&D, Stephen Michael Kelsey, sold 5,367 shares of common stock to cover tax withholding obligations from RSU vesting.

Revolution Medicines, Inc. CEO Mark A. Goldsmith reported a pre-scheduled future sale of 13,411 shares of common stock for September 16, 2025, to cover tax obligations from RSU vesting.

Revolution Medicines' Chief Operating Officer, Margaret Horn, sold 4,775 shares of common stock to cover tax obligations from RSU vesting.

Revolution Medicines General Counsel Jeff Cislini filed a Form 4 detailing a future sale of 1,869 common shares on September 16, 2025, to cover tax obligations from RSU vesting.

Revolution Medicines' CFO, Jack Anders, sold 2,320 shares of common stock on September 16, 2025, at $45.8249 per share to cover tax withholding from RSU vesting.

Revolution Medicines' President of R&D, Stephen Michael Kelsey, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Financial Officer, Jack Anders, executed pre-planned transactions involving the exercise of stock options and subsequent sale of common stock.

Revolution Medicines, Inc. CEO Mark A. Goldsmith reported the exercise of 37,000 stock options, increasing his direct beneficial ownership in the company.

Revolution Medicines, Inc. Director Sandra Horning acquired 3,142 shares of common stock and 11,574 stock options on June 26, 2025, increasing her beneficial ownership in the company.

Revolution Medicines, Inc. Director Sushil Patel reported the acquisition of 3,142 shares of common stock and 11,574 stock options as part of an equity grant on June 26, 2025.

Revolution Medicines, Inc. Director Lorence H. Kim reported the acquisition of 3,142 shares of common stock and 11,574 stock options as part of an equity grant.

Revolution Medicines, Inc. Director and 10% Owner Alexis Borisy reported the acquisition of 3,142 Restricted Stock Units and 11,574 stock options, increasing his beneficial ownership in the company.